帕金森氏症 - KOL的见地

在本报告中，我们根据对KOL 的访谈所获得的见解，研究和分析了帕金森氏症的治疗方法，重点关注现有和正在研发的治疗方法的有效性、挑战和潜力，提供有关当前和未来治疗前景的详细资讯。

企业

目录

摘要整理

现在与未来的治疗流程

调查目的

帕金森氏症的目前治疗惯行和未满足需求

帕金森氏症治疗新的方向性

已批准治疗方法

• 多巴胺促效剂
• 固定用量组合药物(FDC)
• MAO-B抑制剂
• COMT抑制剂
• 其他的药物

开发平台治疗方法

• 多巴胺促效剂
  • Aplindore(DAB 452，Seelos Therapeutics)
  • Tavapadon(AbbVie/Cerevel Therapeutics)
• FDC治疗方法
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612(levodopa + carbidopa subcutaneous infusion，NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001(pramipexole + rasagiline，Pharma Two B)
• 其他的作用机制
  • Nabilone FDT(AOP Orphan Pharmaceuticals)
  • Mesdopetam(Integrative Research Laboratories)
  • Buntanetap(R-phenserine/Posiphen，Annovis Bio)
• 早期阶段的医药品候补
  • Alpha-synuclein inhibitors
  • UCB0599(UCB)
  • PRX002(prasinezumab，Roche)
  • ENT-01(kenterin，Enterin)
  • ION464(Ionis Pharma/Biogen)
  • Radotinib(Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• 其他的作用机制/开发平台(管线)候补

未来的治疗范例

附录

Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.

Key questions answered:

• What treatments currently form the backbone of Parkinson's Disease therapy?
• What are the advantages and disadvantages of these treatments?
• What are the current unmet needs and challenges in treating Parkinson's Disease?
• Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
• Do any of the current pipeline therapies address unmet treatment needs?
• How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?

Key brands covered in this report:

• Alpha-synuclein inhibitors (e.g. cinpanemab, ENT-01, ION464, prasinezumab, UCB0599)
• Buntanetap ((+)(3aR)phenserine)
• Cell/gene therapies and various other early-stage MOAs
• Comtan (entacapone)
• DNL151
• Dostinex (cabergoline)
• Duopa (levodopa/carbidopa intraduodenal)
• IPX203 (carbidopa/levodopa)
• Mesdopetam
• Ongentys (opicapone)
• P2B-001 (pramipexole/rasagiline)
• PRODUODOPA/VYALEV (foscarbidopa/foslevadopa)
• Repurposed drugs (e.g. nilotinib, GLP-1 agonists (exenatide sustained-release, liraglutide, lixisenatide NLY01), etc.)
• Requip franchise (ropinirole/ER)
• Rytary (levodopa/carbidopa ER)
• Stalevo (levodopa/carbidopa/entacapone)

Companies:

Table of Contents

Executive summary

• This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:

Current and future treatment algorithm

Research objectives

Current treatment practice and unmet needs in Parkinson's disease

• Key insights summary
  • First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience

New directions in Parkinson's disease therapy

• Key insights summary
  • Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine

Approved therapies

• Dopamine agonists
  • Key insights summary
• Fixed-dose combination (FDC) agents
  • Key insights summary
• MAO-B inhibitors
  • Key insights summary
• COMT inhibitors
  • Key insights summary
• Other agents
  • Key insights summary

Pipeline therapies

• Dopamine agonists
  • Aplindore (DAB 452; Seelos Therapeutics)
  • Tavapadon (AbbVie/Cerevel Therapeutics)
• FDC therapies
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001 (pramipexole + rasagiline; Pharma Two B)
• Other modes of action
  • Nabilone FDT (AOP Orphan Pharmaceuticals)
  • Mesdopetam (Integrative Research Laboratories)
  • Buntanetap (R-phenserine/Posiphen; Annovis Bio)
• Early-phase drug candidates
  • Alpha-synuclein inhibitors
  • UCB0599 (UCB)
  • PRX002 (prasinezumab; Roche)
  • ENT-01 (kenterin; Enterin)
  • ION464 (Ionis Pharma/Biogen)
  • Radotinib (Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• Other mechanisms of action/pipeline candidates
  • Key insights summary

Future treatment paradigm

• Key insights summary
  • Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe